Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

Clin Endocrinol (Oxf). 2009 Jun;70(6):946-53. doi: 10.1111/j.1365-2265.2008.03415.x. Epub 2008 Sep 10.

Abstract

Objective: No study has evaluated the antiproliferative effects of thiazolidinediones and antiblastics in 'primary cultured human anaplastic thyroid cancer cells'.

Design: Primary anaplastic cells proliferation was evaluated after incubation with increasing concentrations of rosiglitazone or pioglitazone or antiblastics (bleomycin, cisplatin, gemcitabine) by a proliferation assay (WST-1-tetrazolium reaction) and cell counting.

Measurements and results: A reduction of proliferation by thiazolidinediones at 1 h (from the start of tetrazolium reaction) [of 11% and 25%, with rosiglitazone, 10 or 20 (P = 0.0001) microM, respectively; of 7% and 17%, with pioglitazone, 10 or 20 (P = 0.0125) microM, respectively], and at 2 h [of 14% and 24%, with rosiglitazone, 10 (P = 0.0043) or 20 (P < 0.0001) microM, respectively; of 9% and 21%, with pioglitazone, 10 (P = 0.0397) or 20 (P = 0.0001) microM, respectively] was shown. No significant thiazolidinediones effect was observed in normal thyroid follicular cells. Bleomycin, cisplatin and gemcitabine significantly (P < 0.0001) inhibited (> 50%) anaplastic cells proliferation. Cell counting confirmed the above mentioned results. Inhibition of proliferation was similar in tumours with or without (V600E)BRAF mutation, both for thiazolidinediones and antiblastics.

Conclusions: Thiazolidinediones exert an antiproliferative effect in primary cultured human anaplastic carcinoma cells in vitro, such as antiblastics.

MeSH terms

  • Carcinoma / drug therapy*
  • Carcinoma / physiopathology
  • Cell Proliferation / drug effects*
  • Growth Inhibitors / pharmacology*
  • Humans
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / physiopathology
  • Tumor Cells, Cultured

Substances

  • Growth Inhibitors
  • Thiazolidinediones
  • Rosiglitazone
  • Pioglitazone